Literature DB >> 3041238

Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.

D Kerrigan, Y Pommier, K W Kohn.   

Abstract

The two demethylepipodophyllotoxin glycosides, teniposide (VM-26) and etoposide (VP-16), have previously been reported to interact with DNA topoisomerase II by stabilizing a topoisomerase II-DNA covalent intermediate. This study examined the protein-associated aspect of the topoisomerase II-DNA-epipodophyllotoxin lesion. We found that in mouse (L1210) and human (VA-13 and HT-29) log-phase cell cultures, all DNA strand breaks produced by VP-16 or VM-26 were protein-associated. We found also that these protein-associated breaks occurred with a frequency which correlated with cytotoxicity in all three cell lines. For all three cell lines and for both compounds the regression lines were similar. Therefore, for a given class of topoisomerase II inhibitors, it may be possible to generate a characteristic line from which DNA-protein crosslink frequency predicts cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3041238

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  10 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Analysis of TNF alpha-induced DNA strand breaks at the single cell level.

Authors:  K Fehsel; V Kolb-Bachofen; H Kolb
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

3.  Development of a novel assay for human tyrosyl DNA phosphodiesterase 2.

Authors:  Sanjay Adhikari; Soumendra K Karmahapatra; Hadi Elias; Priyanka Dhopeshwarkar; R Scott Williams; Stephen Byers; Aykut Uren; Rabindra Roy
Journal:  Anal Biochem       Date:  2011-05-12       Impact factor: 3.365

Review 4.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

Review 6.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

Authors:  John Nicolette; Mirjam Luijten; Jennifer C Sasaki; Laura Custer; Michelle Embry; Roland Froetschl; George Johnson; Gladys Ouedraogo; Raja Settivari; Veronique Thybaud; Kerry L Dearfield
Journal:  Environ Mol Mutagen       Date:  2021-11-22       Impact factor: 3.579

8.  Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.

Authors:  Ralph Zellweger; Damian Dalcher; Karun Mutreja; Matteo Berti; Jonas A Schmid; Raquel Herrador; Alessandro Vindigni; Massimo Lopes
Journal:  J Cell Biol       Date:  2015-03-02       Impact factor: 10.539

9.  Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Authors:  Kshama A Doshi; Rossana Trotta; Karthika Natarajan; Feyruz V Rassool; Adriana E Tron; Dennis Huszar; Danilo Perrotti; Maria R Baer
Journal:  Oncotarget       Date:  2016-07-26

10.  Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.

Authors:  Hannah C Wise; Gopakumar V Iyer; Kathleen Moore; Sarah M Temkin; Sarah Gordon; Carol Aghajanian; Rachel N Grisham
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.